A vial of the Moderna Covid-19 vaccine and syringes sit prepared at a pop up vaccine clinic at the Jewish Community Center on April 16, 2021 in the Staten Island borough of New York City. Moderna is ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.

This video compares Moderna’s recent Phase 3 win in personalized mRNA cancer therapy to BioNTech’s wider oncology pipeline.

The company is looking to prove it can achieve significant success outside the coronavirus market.

Two names built on the same platform have stopped moving together this morning. Moderna (NASDAQ:MRNA) stock is up 11% to $154.15, a Tuesday morning session standing well apart from anything happening ...

Moderna shares gained 18% last week—finishing it at their highest level in more than four years—after the New York Times ...

BioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines. Both have attractive pipelines that could lead to important new approvals over the next few years.

BioNTech boasts a deep pipeline of candidates. One of the most promising products it is working on is called pumitamig. The biotech is developing it in collaboration with Bristol Myers Squibb(NYSE: ...